LAPOINTE ANTHONY GREGG 4

What Happened

• Anthony LaPointe, a member of Rigel Pharmaceuticals' Board of Directors, was granted 5,750 restricted stock units (RSUs) on 2026-05-15. The reported acquisition price is $0.00, so the immediate reported value is $0. These RSUs convert to Common Stock upon vesting rather than representing an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-15; Form 4 filed: 2026-05-19.
• Grant: 5,750 RSUs at $0.00 per share (reported acquisition value $0).
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: RSUs will fully vest on the date prior to the company’s next Annual Meeting, subject to LaPointe’s continuous service on the Board.
• Timeliness: Form lists the filing date; confirm timeliness against the SEC two-business-day Form 4 rule if this matters to you.

Context

• This was an equity compensation award (A = Award/Grant), not a market purchase or sale. RSU grants are a common way companies compensate directors and typically reflect service-based compensation rather than a direct trading signal. Vesting conditions mean the shares are contingent on continued service and will only be issued if vesting requirements are met.